Evaluation of Long-term Adverse Effects of Gastric Bypass in Omega (OMEGA10)
The omega gastric bypass (OAGB) is developing worldwide as an alternative to the Y gastric bypass (RYGB). Cases of nutrition deficiency after OAGB, in particular protein deficency, are regularly reported in the literature, raising the question of the medium/long-term safety of this procedure. In its technology assessment report issued in September 2019 (HAS, 2019), the Haute Autorité de Santé rules on the invalidity of OAGB with a 200 cm biliary limb and the lack of sufficient data on the safety of OAGB with a 150 cm biliary limb compared to RYGB. The lack of long-term data on weight, resolution of comorbidities, quality of life, and endoscopic evaluation given the risk of lower esophageal cancer is also noted.
The main objective of the study is to compare the incidence of serious adverse events related to surgery after OAGB at 10 years, according to 2 types of loop: a realization with a 150-cm biliary loop (OAGB AB150) versus a realization with a 200-cm biliary loop (OAGB AB200).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Robert CAIAZZO, MD,PhD
- Phone Number: +33 0320445962
- Email: robert.caiazzo@chru-lille.fr
Study Locations
-
-
-
Lille, France
- Recruiting
- Hôpital Claude Huriez - Service de chirurgie générale et endocrinienne
-
Contact:
- Robert Caiazzo
- Phone Number: 03 20 44 42 73
- Email: robert.caiazzo@chru-lille.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
This study involves patients:
- operated between 2008 and 2013 for an OAGB with a 150 or 200cm biliary limb
- fulfilling the HAS criteria(HAS, 2009) at the time of their surgery: BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 associated with a comorbidity likely to be improved by weight loss
- benefiting from a follow-up.
Description
Inclusion Criteria:
- Patients who received 10 ± 2 years ago (between 2009 and 2013) an OAGB with a 150 or 200cm biliary limb. Patients should be consecutive at each center.
- Patients fulfilling the criteria of indication for bariatric surgery at the time of their intervention according to the recommendations of the HAS (HAS, 2009) in an expert center.
- Patients agreeing to perform an endoscopic evaluation with biopsies at 10 years
- Patients who gave their consent
- Patients with health insurance coverage
Exclusion Criteria:
- Contraindication to bariatric surgery defined according to HAS recommendations (HAS, 2009)
- Persons deprived of liberty, under guardianship, or under curatorship
- Patients included in a protocol with a conflict of interest with OMEGA10.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
OAGB150
One anastomosis gastric bypass with 150cm biliary limb
|
Clinical, biological and endoscopic evaluation
|
|
OAGB200
One anastomosis gastric bypass with 200cm biliary limb
|
Clinical, biological and endoscopic evaluation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of serious surgery-related adverse events
Time Frame: 10 years after surgery
|
A serious adverse event is defined as a medical event that requires hospitalization, is life-threatening, results in persistent or substantial disability, or results in death.
The "surgery-related" character will be described by each investigator in the first instance and homogenized by the group of experts designated at the beginning of the study.
|
10 years after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
incidence of serious adverse events not related to surgery
Time Frame: 10 years after surgery
|
10 years after surgery
|
|
|
Nutritional biological status , assessed by evaluation of malnutrition parameters
Time Frame: 10 years after surgery
|
10 years after surgery
|
|
|
Nutritional clinical status, assessed by dietitian evaluation
Time Frame: 10 years after surgery
|
10 years after surgery
|
|
|
Excess weight loss percentage
Time Frame: 10 years after surgery
|
calculated as follows: (weight at 10 years - initial weight) / (initial weight - ideal weight) x 100 The ideal weight is defined as the weight corresponding to a BMI = 25 kg/m2.
The initial weight is the weight on the day of surgery.
|
10 years after surgery
|
|
Metabolic comorbidities remission
Time Frame: 10 years after surgery
|
10 years after surgery
|
|
|
Diabetes remission
Time Frame: 10 years after surgery
|
10 years after surgery
|
|
|
Hypertension remission
Time Frame: 10 years after surgery
|
10 years after surgery
|
|
|
Obstructive sleep apnea remission
Time Frame: 10 years after surgery
|
10 years after surgery
|
|
|
Dyslipidemia remission
Time Frame: 10 years after surgery
|
10 years after surgery
|
|
|
Quality of life by BAROS score (Bariatric analysis and reporting outcome system)
Time Frame: 10 years after surgery
|
10 years after surgery
|
|
|
Quality of life by GIQLI score (Gastro Intestinal Quality of Life index) questionnaires
Time Frame: 10 years after surgery
|
The GIQLI is a score to evaluate digestive disorders in 36 items, ranging from 0 (the worst quality of life) to 144 (the best quality of life).
|
10 years after surgery
|
|
GERD
Time Frame: 10 years after surgery
|
GERD, assessed by clinical evaluation, PPI use, and endoscopic signs of GERD (gastritis, oesophagitis, anastomotic ulcer, Barrett's esophagus, gastric metaplasia, esophageal metaplasia
|
10 years after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Robert Caiazzo, MD,PhD, University Hospital, Lille
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nutrition Disorders
- Overnutrition
- Body Weight
- Digestive System Diseases
- Gastrointestinal Diseases
- Esophageal Diseases
- Overweight
- Esophageal Motility Disorders
- Deglutition Disorders
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Obesity
- Gastroesophageal Reflux
Other Study ID Numbers
Other Study ID Numbers
- 2020_82
- 2020-A03156-33 (Other Identifier: ID-RCB number,ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.